OTCMKTS:BIOVF Q3 EPS Estimate Cut by HC Wainwright

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) – Research analysts at HC Wainwright lowered their Q3 2026 earnings estimates for shares of Swedish Orphan Biovitrum in a report released on Friday, July 17th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of $0.63 for the quarter, down from their prior estimate of $0.69. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Swedish Orphan Biovitrum’s current full-year earnings is $1.94 per share. HC Wainwright also issued estimates for Swedish Orphan Biovitrum’s Q4 2026 earnings at $0.60 EPS, FY2026 earnings at $1.94 EPS, Q1 2027 earnings at $0.62 EPS, Q2 2027 earnings at $0.68 EPS, Q3 2027 earnings at $1.05 EPS, Q4 2027 earnings at $1.03 EPS and FY2027 earnings at $3.36 EPS.

Other equities research analysts have also issued research reports about the company. Zacks Research upgraded Swedish Orphan Biovitrum to a “hold” rating in a research note on Thursday, May 7th. Pareto Securities downgraded Swedish Orphan Biovitrum to a “hold” rating in a report on Monday, June 29th. Barclays reissued an “overweight” rating on shares of Swedish Orphan Biovitrum in a research report on Friday, July 3rd. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Swedish Orphan Biovitrum in a research report on Tuesday. Four investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy”.

Swedish Orphan Biovitrum Stock Performance

OTCMKTS:BIOVF opened at $49.03 on Monday. The business’s 50-day moving average is $48.02 and its two-hundred day moving average is $42.39. The firm has a market capitalization of $17.45 billion, a PE ratio of 108.95 and a beta of 0.35. Swedish Orphan Biovitrum has a 12 month low of $28.93 and a 12 month high of $49.03. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.70 and a quick ratio of 0.47.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last posted its earnings results on Tuesday, April 28th. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.07. Swedish Orphan Biovitrum had a net margin of 4.74% and a return on equity of 18.27%. The business had revenue of $755.76 million for the quarter, compared to analyst estimates of $749.76 million.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.